KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Retained Earnings (2016 - 2025)

Emergent BioSolutions' Retained Earnings history spans 16 years, with the latest figure at -$7.5 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 96.47% year-over-year to -$7.5 million; the TTM value through Dec 2025 reached -$7.5 million, up 96.47%, while the annual FY2025 figure was -$7.5 million, 96.47% up from the prior year.
  • Retained Earnings reached -$7.5 million in Q4 2025 per EBS's latest filing, roughly flat from -$7.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $950.3 million in Q4 2021 to a low of -$295.9 million in Q2 2024.
  • Average Retained Earnings over 5 years is $114.1 million, with a median of -$6.8 million recorded in 2025.
  • Peak YoY movement for Retained Earnings: soared 6024.73% in 2023, then tumbled 18393.75% in 2024.
  • A 5-year view of Retained Earnings shows it stood at $950.3 million in 2021, then tumbled by 99.67% to $3.1 million in 2022, then tumbled by 283.87% to -$5.7 million in 2023, then tumbled by 3626.32% to -$212.4 million in 2024, then surged by 96.47% to -$7.5 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Retained Earnings are -$7.5 million (Q4 2025), -$7.5 million (Q3 2025), and -$156.4 million (Q2 2025).